Metformin is the first-line pharmacological therapy for type 2 diabetes mellitus (T2DM). Although gastrointestinal (GI) adverse effects are common, persistent symptoms resembling irritable bowel syndrome (IBS) are less frequently reported. We present the case of a 56-year-old male with T2DM who developed metformin-induced IBS-like symptoms (IBS -D) characterized by abdominal cramping, bloating, and postprandial diarrhoea triggered by specific dietary factors. Symptoms significantly worsened following metformin dose escalation from 500 mg to 750 mg daily. Laboratory evaluation revealed adequate glycemic control with fasting blood glucose of 140 mg/dL and HbA1c of 6.5%. After discontinuation of metformin and initiation of dapagliflozin 10 mg daily along with dietary modification, gastrointestinal symptoms markedly improved while glycemic control remained stable. This case highlights the importance of recognizing metformin-induced IBS-like symptoms and considering alternative antidiabetic therapies when intolerance occurs.